(firstQuint)SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor).

 Trametinib and pazopanib are independently approved for other cancers.

 Both drugs work to inhibit tumor development in different ways.

 Combining these drugs may lead to improved disease control.

 The purpose of this study is to evaluate the effect of the combination of both drugs on advanced gastrointestinal stromal tumors.

.

 SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)@highlight

This study evaluates the combination of trametinib and pazopanib in patients with advanced gastrointestinal stromal tumors (GIST).

